Modality
Gene Editing
MOA
IL-17i
Target
Tau
Pathway
Innate Imm
Ovarian CaNB
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
Jan 2020
→ Apr 2027
Phase 2Current
NCT07745227
2,566 pts·Ovarian Ca
2020-01→2027-04·Active
NCT07573129
1,032 pts·Ovarian Ca
2024-08→2026-04·Completed
3,598 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-233w awayPh2 Data· Ovarian Ca
2027-04-061.0y awayPh2 Data· Ovarian Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2
Active
P2
Complet…
Catalysts
Ph2 Data
2026-04-23 · 3w away
Ovarian Ca
Ph2 Data
2027-04-06 · 1.0y away
Ovarian Ca
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07745227 | Phase 2 | Ovarian Ca | Active | 2566 | EASI-75 |
| NCT07573129 | Phase 2 | Ovarian Ca | Completed | 1032 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |